Blood biomarkers and treatment response in major depression

Cristina Mora, Valentina Zonca, Marco A. Riva, Annamaria Cattaneo

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Millions of people worldwide suffer from depression, but despite advances in pharmacological therapies, many patients do not experience symptomatic remission or treatment response, even after treatments with several medications. As such, there is an urgent need to identify biomarkers that can not only predict the treatment response but also allow a rational selection of optimal therapy for each patient. Areas covered: This review examines the recent findings, coming from different ‘omic sciences,’ in human blood-based biomarkers associated with antidepressant treatment response with particular attention on genetic/epigenetic and biochemical biomarkers. Specific emphasis will be placed on key molecules related to neuroplasticity and inflammation because of their involvement in the pathophysiology of depression and antidepressant response. Expert commentary: Biomarker identification is still an ongoing work. Indeed, to date, no biomarkers have sufficiently proven specificity, sensitivity, and reproducibility to be used in the clinical setting. However, ‘omic’ approaches hold great promise in identifying multiple features for predicting antidepressant response, making a personalized treatment strategy possible for each patient, and thereby assist with quick and efficacious responsiveness. It is thus necessary that future studies take an integrative approach that includes clinical assessment, environment influences, and molecular and biological biomarkers.

Original languageEnglish
Pages (from-to)513-529
Number of pages17
JournalExpert Review of Molecular Diagnostics
Volume18
Issue number6
DOIs
Publication statusPublished - Jun 3 2018

Fingerprint

Biomarkers
Antidepressive Agents
Therapeutics
Neuronal Plasticity
Epigenomics
Molecular Biology
Pharmacology
Inflammation
Sensitivity and Specificity

Keywords

  • biomarkers
  • cytokines
  • epigenomics
  • major depressive disorder
  • pharmacogenomics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Blood biomarkers and treatment response in major depression. / Mora, Cristina; Zonca, Valentina; Riva, Marco A.; Cattaneo, Annamaria.

In: Expert Review of Molecular Diagnostics, Vol. 18, No. 6, 03.06.2018, p. 513-529.

Research output: Contribution to journalReview article

Mora, Cristina ; Zonca, Valentina ; Riva, Marco A. ; Cattaneo, Annamaria. / Blood biomarkers and treatment response in major depression. In: Expert Review of Molecular Diagnostics. 2018 ; Vol. 18, No. 6. pp. 513-529.
@article{f93c712394ac46bc8821a4f4dfbe2bb3,
title = "Blood biomarkers and treatment response in major depression",
abstract = "Introduction: Millions of people worldwide suffer from depression, but despite advances in pharmacological therapies, many patients do not experience symptomatic remission or treatment response, even after treatments with several medications. As such, there is an urgent need to identify biomarkers that can not only predict the treatment response but also allow a rational selection of optimal therapy for each patient. Areas covered: This review examines the recent findings, coming from different ‘omic sciences,’ in human blood-based biomarkers associated with antidepressant treatment response with particular attention on genetic/epigenetic and biochemical biomarkers. Specific emphasis will be placed on key molecules related to neuroplasticity and inflammation because of their involvement in the pathophysiology of depression and antidepressant response. Expert commentary: Biomarker identification is still an ongoing work. Indeed, to date, no biomarkers have sufficiently proven specificity, sensitivity, and reproducibility to be used in the clinical setting. However, ‘omic’ approaches hold great promise in identifying multiple features for predicting antidepressant response, making a personalized treatment strategy possible for each patient, and thereby assist with quick and efficacious responsiveness. It is thus necessary that future studies take an integrative approach that includes clinical assessment, environment influences, and molecular and biological biomarkers.",
keywords = "biomarkers, cytokines, epigenomics, major depressive disorder, pharmacogenomics",
author = "Cristina Mora and Valentina Zonca and Riva, {Marco A.} and Annamaria Cattaneo",
year = "2018",
month = "6",
day = "3",
doi = "10.1080/14737159.2018.1470927",
language = "English",
volume = "18",
pages = "513--529",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Blood biomarkers and treatment response in major depression

AU - Mora, Cristina

AU - Zonca, Valentina

AU - Riva, Marco A.

AU - Cattaneo, Annamaria

PY - 2018/6/3

Y1 - 2018/6/3

N2 - Introduction: Millions of people worldwide suffer from depression, but despite advances in pharmacological therapies, many patients do not experience symptomatic remission or treatment response, even after treatments with several medications. As such, there is an urgent need to identify biomarkers that can not only predict the treatment response but also allow a rational selection of optimal therapy for each patient. Areas covered: This review examines the recent findings, coming from different ‘omic sciences,’ in human blood-based biomarkers associated with antidepressant treatment response with particular attention on genetic/epigenetic and biochemical biomarkers. Specific emphasis will be placed on key molecules related to neuroplasticity and inflammation because of their involvement in the pathophysiology of depression and antidepressant response. Expert commentary: Biomarker identification is still an ongoing work. Indeed, to date, no biomarkers have sufficiently proven specificity, sensitivity, and reproducibility to be used in the clinical setting. However, ‘omic’ approaches hold great promise in identifying multiple features for predicting antidepressant response, making a personalized treatment strategy possible for each patient, and thereby assist with quick and efficacious responsiveness. It is thus necessary that future studies take an integrative approach that includes clinical assessment, environment influences, and molecular and biological biomarkers.

AB - Introduction: Millions of people worldwide suffer from depression, but despite advances in pharmacological therapies, many patients do not experience symptomatic remission or treatment response, even after treatments with several medications. As such, there is an urgent need to identify biomarkers that can not only predict the treatment response but also allow a rational selection of optimal therapy for each patient. Areas covered: This review examines the recent findings, coming from different ‘omic sciences,’ in human blood-based biomarkers associated with antidepressant treatment response with particular attention on genetic/epigenetic and biochemical biomarkers. Specific emphasis will be placed on key molecules related to neuroplasticity and inflammation because of their involvement in the pathophysiology of depression and antidepressant response. Expert commentary: Biomarker identification is still an ongoing work. Indeed, to date, no biomarkers have sufficiently proven specificity, sensitivity, and reproducibility to be used in the clinical setting. However, ‘omic’ approaches hold great promise in identifying multiple features for predicting antidepressant response, making a personalized treatment strategy possible for each patient, and thereby assist with quick and efficacious responsiveness. It is thus necessary that future studies take an integrative approach that includes clinical assessment, environment influences, and molecular and biological biomarkers.

KW - biomarkers

KW - cytokines

KW - epigenomics

KW - major depressive disorder

KW - pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=85048373936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048373936&partnerID=8YFLogxK

U2 - 10.1080/14737159.2018.1470927

DO - 10.1080/14737159.2018.1470927

M3 - Review article

C2 - 29701114

AN - SCOPUS:85048373936

VL - 18

SP - 513

EP - 529

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 6

ER -